AbbVie Stock Forecast: Trending Strong Buy Among Analysts

AbbVie (ABBV) stock has risen 6.3% over the past week, slipped 0.9% in the last month, and gained 12.9% over the past year, reflecting a mix of short-term volatility and steady longer-term growth. Wall Street’s analysts are strongly bullish, forecasting upside from the current $211.32 level toward an average 12‑month price target of $254.37.

Gary Nachman (Canaccord Genuity LLC (US)) reiterated AbbVie as a Buy on April 30, 2026 and raised his price target to $265.00, signaling meaningful upside from current levels. This N-star analyst ranks #8078 out of 12160 on TipRanks, with a 45.62% success rate and a 0.00% average return per rating.

Nachman points to a solid first quarter that showed good momentum across AbbVie’s key growth drivers in Immunology and Neuro, along with some upside in Oncology and Aesthetics where expectations had been lower. International performance was particularly strong, and AbbVie raised its 2026 revenue and EPS guidance, supported mainly by Immunology and Neuro strength.

The analyst highlights that key drugs Skyrizi and Rinvoq in Immunology, and Vraylar and the Migraine portfolio in Neuro, are outperforming and still underappreciated by the market, with new indications and combination approaches expected to drive further growth. AbbVie’s Neuro franchise is also seen as a budding powerhouse, with Parkinson’s treatments like Vyalev and the expected U.S. approval of Tavapadon in the third quarter projected to support a peak Parkinson’s franchise of over $5 billion.

Nachman underscores that AbbVie’s broader pipeline and its capacity for future deals are not fully reflected in the stock, even as management walks through multiple advancing programs in Oncology, Aesthetics, obesity, depression, and immunology combinations. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.